Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop

Roch Houot (1) , P. Gaulard , R. Schreiber (2) , I. Mellman , O. Lambotte (3, 4, 5) , P.G. Coulie , T. Fest (1) , A. Korman , R. Levy (1, 6) , M. Shipp , K. Tarte (1) , H. Kohrt , A. Marabelle (7) , S. Ansell , Herve Watier (8) , A. Van Elsas , A. Balakumaran , F. Arce Vargas , S.A. Quezada , G. Salles (9) , D. Olive

1 MiCa - Microenvironnement et cancer
2 Department of Physiology
3 INSERM
4 UP11 - Université Paris-Sud - Paris 11
5 Département de Médecine Interne et Maladies Infectieuses
6 ONERA - The French Aerospace Lab [Palaiseau]
7 UMR 1015 - Immunologie des tumeurs et immunothérapie
8 GICC UMR 7292 CNRS - Génétique, immunothérapie, chimie et cancer (GICC), UMR 7292 CNRS [2012-2017]
9 Service d'hématologie [Hôpital Edouard Herriot - HCL]

In November 2015, the CALYM Carnot Institute held a 2-d workshop to discuss the current and future development of immunomodulatory antibodies for the treatment of lymphoma. Highlights from the workshop are presented in this article.

Keywords: Immunomodulation; immunotherapy; lymphoma; programmed cell death 1 ligand 1; programmed cell death 1 receptor

Domains: Life Sciences [q-bio]; Cancer

Roch Houot, P. Gaulard, R. Schreiber, I. Mellman, O. Lambotte, et al.. Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. OncoImmunology, 2016, 5 (7), pp.e1186323. ⟨10.1080/2162402X.2016.1186323⟩. ⟨hal-01372753⟩